Covance Daytona Beach Clinical Research Unit
Daytona Beach, Florida, 32117, United States
NCT Number: NCT03291782
This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs).
In food effect cohort, subjects will each receive 2 doses of D-0120-NA in an open-label manner; once in the fasted state and once in the fed state.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Daytona Beach, Florida, 32117, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral, single dose
Time frame: 2 weeks
Adverse Events and changes of Laboratory, Electrocardiogram, and Vital Signs
Time frame: Day-1 through 3
AUC: area under the plasma concentration versus time curve for D-0120
Time frame: Day-1 through 3
Cmax: maximum plasma drug concentration of D-0120
Time frame: Day-1 through 3
Tmax: Time to reach the Cmax of D-0120
Time frame: Day-1 through 3
t1/2: apparent terminal half-life of D-0120
Time frame: Day-1 through 3
CL/F: Apparent oral clearance of D-0120
Time frame: Day-1 through 3
Vz/F: Apparent volume of distribution of D-0120
Time frame: Day-1 through 3
Profile in terms of Serum uric acid and creatinine; Urine uric acid and creatinine. These parameters will be combined to report fractional excretion of uric acid (FEUa %)
InventisBio Co., Ltd
Industry
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05499312
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shatin, Hong Kong
View Trial DetailsNCT05665699
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06229145
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06969469
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Taipei, Taiwan
View Trial Details